Subconjunctival bevacizumab immediately after excision of primary pterygium: The first clinical trial

Cornea

Volumn 30, Issue 11, 2011, Pages 1219-1222

  Shenasi, Abdollah ^a   Mousavi, Farideh ^a   Shoa Ahari, Solmaz ^a   Rahimi Ardabili, Babak ^a   Fouladi, Rohollah Fadaei ^a  

^a TABRIZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

bevacizumab; pterygium; recurrence

Indexed keywords

BEVACIZUMAB; PLACEBO;

ADULT; AGED; ARTICLE; CONJUNCTIVA DISEASE; CONSERVATIVE TREATMENT; CONTROLLED STUDY; CORNEA DISEASE; CORNEA EPITHELIUM; CORNEA ULCER; DELLEN FORMATION; DOUBLE BLIND PROCEDURE; DRUG TOLERABILITY; EXCISION; EYE SURGERY; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; PTERYGIUM; PYOGENIC GRANULOMA; RANDOMIZED CONTROLLED TRIAL; RECURRENCE RISK; SINGLE DRUG DOSE;

ADULT; AGED; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; COMBINED MODALITY THERAPY; CONJUNCTIVA; DOUBLE-BLIND METHOD; FEMALE; FOLLOW-UP STUDIES; HUMANS; INJECTIONS, INTRAOCULAR; MALE; MIDDLE AGED; OPHTHALMOLOGIC SURGICAL PROCEDURES; PTERYGIUM; RECURRENCE; TREATMENT OUTCOME; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 80053621495     PISSN: 02773740     EISSN: 15364798     Source Type: Journal    
DOI: 10.1097/ICO.0b013e31820ca63f     Document Type: Article

References (39)

1. Jin J, Guan M, Sima J, et al. Decreased pigment epithelium-derived factor and increased vascular endothelial growth factor levels in pterygia. Cornea. 2003;22:473-477. (Pubitemid 36759043)
2. Sebban A, Hirst LW. Pterygium recurrence rate at the Princess Alexandra Hospital. Aust N Z J Ophthalmol. 1991;19:203-206.
3. Coroneo MT, Di Girolamo N, Wakefield D. The pathogenesis of pterygia. Curr Opin Ophthalmol. 1999;10:282-288. (Pubitemid 30339430)
4. Lee DH, Cho HJ, Kim JT, et al. Expression of vascular endothelial growth factor and inducible nitric oxide synthase in pterygia. Cornea. 2001;20: 738-742. (Pubitemid 34506473)
5. Kuo CH, Miyazaki D, Nawata N, et al. Prognosis-determinant candidate genes identified by whole genome scanning in eyes with pterygia. Invest Ophthalmol Vis Sci. 2007;48:3566-3575. (Pubitemid 351261091)
6. Raiskup F, Solomon A, Landau D, et al. Mitomycin C for pterygium: Long term evaluation. Br J Ophthalmol. 2004;88:1425-1428. (Pubitemid 39424724)
7. Gebhardt M, Mentlein R, Schaudig U, et al. Differential expression of vascular endothelial growth factor implies the limbal origin of pterygia. Ophthalmology. 2005;112:1023-1030. (Pubitemid 40797457)
8. Aspiotis M, Tsanou E, Gorezis S, et al. Angiogenesis in pterygium: Study of microvessel density, vascular endothelial growth factor, and thrombospondin- 1. Eye (Lond). 2007;21:1095-1101. (Pubitemid 47263760)
9. Marcovich AL, Morad Y, Sandbank J, et al. Angiogenesis in pterygium: Morphometric and immunohistochemical study. Curr Eye Res. 2002;25: 17-22. (Pubitemid 36120910)
10. van SG, Aspiotis M, Blalock TD, et al. Connective tissue growth factor in pterygium: Simultaneous presence with vascular endothelial growth factor possible contributing factor to conjunctival scarring. Graefes Arch Clin Exp Ophthalmol. 2003;241:135-139. (Pubitemid 36747801)
11. Ferrara N, Hillan KJ, Gerber HP, et al. Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat Rev Drug Discov. 2004;3:391-400. (Pubitemid 38618122)
12. Grisanti S, Ziemssen F. Bevacizumab: Off-label use in ophthalmology. Indian J Ophthalmol. 2007;55:417-420.
13. Iliev ME, Domig D, Wolf-Schnurrbursch U, et al. Intravitreal bevacizumab (Avastin) in the treatment of neovascular glaucoma. Am J Ophthalmol. 2006;142:1054-1056. (Pubitemid 44853889)
14. Jorge R, Costa RA, Calucci D, et al. Intravitreal bevacizumab (Avastin) for persistent new vessels in diabetic retinopathy (IBEPE study). Retina. 2006;26:1006-1013. (Pubitemid 44973219)
15. Gunther JB, Altaweel MM. Bevacizumab (Avastin) for the treatment of ocular disease. Surv Ophthalmol. 2009;54:372-400.
16. Manzano RP, Peyman GA, Khan P, et al. Inhibition of experimental corneal neovascularisation by bevacizumab (Avastin). Br J Ophthalmol. 2007;91:804-807. (Pubitemid 46846656)
17. Wu PC, Kuo HK, Tai MH, et al. Topical bevacizumab eyedrops for limbalconjunctival neovascularization in impending recurrent pterygium. Cornea. 2009;28:103-104.
18. Teng CC, Patel NN, Jacobson L. Effect of subconjunctival bevacizumab on primary pterygium. Cornea. 2009;28:468-470.
19. Leippi S, Grehn F, Geerling G. Antiangiogenic therapy for pterygium recurrence. Ophthalmologe. 2009;106:413-419.
20. Mansour AM. Treatment of inflamed pterygia or residual pterygial bed. Br J Ophthalmol. 2009;93:864-865.
21. Bahar I, Kaiserman I, McAllum P, et al. Subconjunctival bevacizumab injection for corneal neovascularization in recurrent pterygium. Curr Eye Res. 2008;33:23-28. (Pubitemid 351156952)
22. Alpay A, Uĝurbasx SH, Erdoĝan B. Comparing techniques for pterygium surgery. Clin Ophthalmol. 2009;3:69-74.
23. Ali AM, Thariat J, Bensadoun RJ, et al. The role of radiotherapy in the treatment of pterygium: A review of the literature including more than 6000 treated lesions. Cancer Radiother. 2010 [epub ahead of print].
24. Khakshoor H, Razavi ME, Daneshvar R, et al. Preoperative subpterygeal injection vs intraoperative mitomycin C for pterygium removal: Comparison of results and complications. Am J Ophthalmol. 2010;150:193-198.
25. Frucht-Pery J, Raiskup F, Ilsar M, et al. Conjunctival autografting combined with low-dose mitomycin C for prevention of primary pterygium recurrence. Am J Ophthalmol. 2006;141:1044-1050.
26. Pikkel J, Porges Y, Ophir A. Halting pterygium recurrence by postoperative 5-fluorouracil. Cornea. 2001;20:168-171. (Pubitemid 32174086)
27. Bekibele CO, Baiyeroju AM, Ajayi BG. 5-fluorouracil vs. betairradiation in the prevention of pterygium recurrence. Int J Clin Pract. 2004;58:920-923. (Pubitemid 39642612)
28. Prabhasawat P, Tesavibul N, Leelapatranura K, et al. Efficacy of subconjunctival 5-fluorouracil and triamcinolone injection in impending recurrent pterygium. Ophthalmology. 2006;113:1102-1109. (Pubitemid 43947236)
29. Bekibele CO, Baiyeroju AM, Olusanya BA, et al. Pterygium treatment using 5-FU as adjuvant treatment compared to conjunctiva autograft. Eye (Lond). 2008;22:31-34.
30. Valezi VG, Schellini SA, Viveiros MM, et al. Safety and efficacy of intraoperative 5-fluorouracil infiltration in pterygium treatment. Arq Bras Oftalmol. 2009;72:169-173.
31. Isohashi F, Inoue T, Xing S, et al. Postoperative irradiation for pterygium: Retrospective analysis of 1,253 patients from the Osaka University Hospital. Strahlenther Onkol. 2006;182:437-442. (Pubitemid 44214486)
32. Nieuwendaal CP, van der Meulen IJ, Mourits M, et al. Long-term followup of pterygium surgery using a conjunctival autograft and Tissucol. Cornea. 2010 [epub ahead of print].
33. Sarnicola V, Vannozzi L, Motolese PA. Recurrence rate using fibrin glueassisted ipsilateral conjunctival autograft in pterygium surgery: 2-year follow-up. Cornea. 2010;29:1211-1214.
34. Mery G, Maalouf T, George JL, et al. Limbal-conjunctival autograft in pterygium surgery. J Fr Ophtalmol. 2010;33:92-98.
35. Ozkurt YB, Kocams O, Comez AT, et al. Treatment of primary pterygium. Optom Vis Sci. 2009;86:1178-1181.
36. Ozer A, Yildirim N, Erol N, et al. Long-term results of bare sclera, limbalconjunctival autograft and amniotic membrane graft techniques in primary pterygium excisions. Ophthalmologica. 2009;223:269-273.
37. Jain AK, Bansal R, Sukhija J. Human amniotic membrane transplantation with fibrin glue in management of primary pterygia: A new tuck-in technique. Cornea. 2008;27:94-99.
38. Ang LP, Chua JL, Tan DT. Current concepts and techniques in pterygium treatment. Curr Opin Ophthalmol. 2007;18:308-313. (Pubitemid 46955297)
39. Mauro J, Foster CS. Pterygia: Pathogenesis and the role of subconjunctival bevacizumab in treatment. Semin Ophthalmol. 2009;24:130-134.